Dr. Mookerjee

Bijoyesh P. Mookerjee, MD

Contact Dr. Mookerjee

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
  2. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
  3. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
  4. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial
  5. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
  6. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial
  7. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
  8. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study
  9. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)
  10. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
  11. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  12. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  13. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  14. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  15. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  16. T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions
  17. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  18. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  19. Cytoprotection in acute myelogenous leukemia (AML) therapy
  20. Overcoming drug resistance: Targeting more than one site